For the first time, Prime Therapeutics hosted the AMCP Nexus specialty keynote, addressing trends in cell and gene therapy and rare disease and immunology categories

research 8 research posters presented by Prime at the 2024 AMCP Annual Meeting Prime remains at the forefront of researching real-world drug utilization, managed care pharmacy programs, and costs...

AMCP Annual Meeting 2025 research posters Studies include Prime’s GLP-1 obesity research and a Medicare drug cost predictive model Click on the poster image to view the full-size version. Prime...

Drs. Tracey Garcia and Amy Pappas, board-certified neurologists, reviewed migraine risk factors and treatments in a recent webinar moderated by Dr. Marci Chodroff, vice president of medical affairs

Breadcrumb Home Newsroom Custom Content Publications FDA Decisions Expected: October 2024 PUBLICATIONS FDA Decisions Expected: October 2024 Your monthly synopsis of new drugs expected to hit the...

Read Drug Approvals Monthly Update: August 2024 This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals provides a review of newly approved specialty drugs, new...

publications Weight management: A holistic journey May 1, 2024 Obesity is a global epidemic and major public health issue that has grown in prevalence over recent decades in adults, adolescents...

PUBLICATIONS FDA Decisions Expected: July 2025 Your monthly synopsis of new drugs expected to hit the market June 18, 2025 Drug pipeline for July 2025 At Prime Therapeutics (Prime), we have...

Marquee event showcased new Prime, our energy, ambition and transformative journey

Perspectives High-Cost Therapy Profile: March Detailed information about Sotatercept Subcutaneous (SC) High Cost Therapy Profile Cardiovascular Sotatercept Subcutaneous (SC) Merck/Bristol-Myers...

publications High-Cost Therapy Profile: June 2025 Zopapogene imadenovec Subcutaneous (SC) | Precigen, Inc. Infectious Disease June 18, 2025 Proposed indications Recurrent respiratory...

Drug Approvals Quarterly Update: April 2024 This wrap-up provides a review of newly approved drugs, recent drug launches, new indications and news of note on drugs in the approval process....

publications High Cost Therapy Profile: January 2025 Tabelecleucel Intravenous (IV) Oncology January 8, 2025 Proposed indications Epstein-Barr virus-positive (EBV+) post-transplant...

Help lower costs with biosimilars We actively promote evidence-based use of biosimilars to help you make the most of your integrated drug strategy. Breadcrumb Home Our solutions Condition...

Special Investigations Unit helps promote safety to prevent fraud, waste and abuse schemes

publications Drug Approvals: July 2024 Monthly update on newly approved specialty and traditional drugs, new indications and first-time generic launches July 31, 2024 Specialty New drugs Jun. 20,...

Expert Clinical Network Insights Hemophilia December 17, 2024 Medication insights: marstacimab-hncq (Hympavzi) The U.S. Food and Drug Administration (FDA) approved marstacimab-hncq (Hympavzi) in...

publications Drug Approvals: February 2025 Monthly update on newly approved specialty and traditional drugs, new indications and first-time generic launches February 28, 2025 Specialty New drugs...

Stories, perspectives and news coverage of Prime Therapeutics/Magellan Rx from AMCP 2024

In this episode, our experts discuss Prime’s four primary tenets of practice for chronic weight management.